News

March 17, 2017March 17, 2017

Phase 2 Study of V565, Anti-TNF Antibody, in Crohn’s Patients Begins

News

VHsquared announced the first patients have entered HARBOR, an international Phase 2 clinical trial examining the efficacy of V565 ( an anti-TNFα oral antibody) in treating Crohn’s disease. The study is ... Read more

March 16, 2017

Ferring and ICF to Develop IBD Treatment for Anal Fissures

News

Ferring Pharmaceuticals is collaborating with the Instituto de Ciencias Farmaceuticas (ICF, based in Brazil) to develop a potential new treatment for anal fissures for patients with inflammatory bowel disease (IBD). The mucoadhesive ... Read more

March 15, 2017

Certain Bacteria Within Gut Microbiome May Halt Inflammation Naturally, Study Says

News

Bacteria naturally present in our gut may be central for reversing inflammation detected in gut inflammatory diseases, such as inflammatory bowel disease (IBD). That finding was reported in the study “NLRP12 ... Read more

March 14, 2017

New Phase 2 Trials to Evaluate Filgotinib in Two Types of Crohn’s Disease

News

Galapagos NV, collaborating with Gilead Sciences, will soon begin recruiting for announced two new Phase 2 clinical trials to evaluate filgotinib in patients with small bowel Crohn’s disease, as well ... Read more

March 13, 2017March 13, 2017

Baker’s Yeast Worsens Crohn’s Disease, Study Suggests

News

The common yeast strain Saccharomyces cerevisiae, also known as Baker’s yeast, may aggravate Crohn’s disease, research suggests. The study, “A member of the gut mycobiota modulates host purine metabolism exacerbating ... Read more

March 10, 2017

Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial

News

Positive interim results were reported in the first two groups of ulcerative colitis patients being treated with Brilacidin (PMX-30063) in a dose-escalating Phase 2 clinical trial. Patients for a third and final group — ... Read more

March 9, 2017

Nominations Sought for Sherman Prize Honoring Bowel Disease Achievements

News

Nominations for the 2017 Sherman Prize, which will honor exceptional achievements in the fight against Crohn’s disease and ulcerative colitis (UC), will be accepted through April 30, according to the ... Read more

March 8, 2017

AXIM Starts Phase 2 IBS Trial of CanChew Plus Cannabinoid-based Gum

News

AXIM Biotechnologies has enrolled 40 patients with irritable bowel syndrome (IBS) and initiated a Phase 2 clinical trial evaluating the effectiveness of its CanChew Plus cannabinoid (CBD)-based chewing gum for ... Read more

March 7, 2017

Epigenetic Enzyme Found Lacking in Some Patients with Crohn’s Disease, Study Suggests

News

Understanding epigenetic mechanisms — changes in gene expression that do not involve changing a gene’s DNA sequence itself — regulating intestinal health may lead to tailored inflammatory bowel disease (IBD) therapies, new ... Read more

March 6, 2017March 6, 2017

Farm Use of Antibiotics Sparks Fears that Bacterial Resistance Could Spread IBD, Other Diseases

News

The growing use of antibiotics in conventional farming may lead to bacterial resistance to some lifesaving human medicines — making it harder to treat illnesses such as inflammatory bowel disease (IBD). The ... Read more